Jason Chesney

30.7k total citations · 6 hit papers
191 papers, 11.7k citations indexed

About

Jason Chesney is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jason Chesney has authored 191 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Oncology, 79 papers in Molecular Biology and 56 papers in Cancer Research. Recurrent topics in Jason Chesney's work include CAR-T cell therapy research (76 papers), Cancer, Hypoxia, and Metabolism (50 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Jason Chesney is often cited by papers focused on CAR-T cell therapy research (76 papers), Cancer, Hypoxia, and Metabolism (50 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Jason Chesney collaborates with scholars based in United States, Spain and United Kingdom. Jason Chesney's co-authors include Richard Bucala, Sucheta Telang, Michael Bacher, Brian F. Clem, Christine N. Metz, Anthony Cerami, Lori Spiegel, M. Michele Hogan, Amy Clem and Abdullah Yalçın and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Jason Chesney

185 papers receiving 11.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair

1994 1.0k citations Richard Bucala, Jason Chesney et al. profile →
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

2009 934 citations Jedd D. Wolchok, Dirk Schadendorf et al. profile →
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.

1996 589 citations Jason Chesney, Richard Bucala et al. profile →
Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response

2001 508 citations Robert A. Mitchell, Jason Chesney et al. profile →
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

2017 471 citations Jason Chesney, Omid Hamid et al. profile →
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

2018 408 citations Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Jason Chesney

Since Specialization

Citations

This map shows the geographic impact of Jason Chesney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Chesney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Chesney more than expected).

Fields of papers citing papers by Jason Chesney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Chesney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Chesney. The network helps show where Jason Chesney may publish in the future.

Co-authorship network of co-authors of Jason Chesney

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Chesney. A scholar is included among the top collaborators of Jason Chesney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Chesney. Jason Chesney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors 2025 ·Cancer Communications ·Harriet M. Kluger, Götz Ulrich Grigoleit, Sajeve Thomas, Evidio Domingo‐Musibay, Jason Chesney, Miguel F. Sanmamed, Theresa Medina, Mirjana Ziemer, Eric D. Whitman, Friedrich Graf Finckenstein, Brian Gastman, Jeffrey Chou, Xiao Wu, Giri Sulur, Rana Fiaz, (unknown), Amod A. Sarnaik	3
2	Single-cell transcriptomics of melanoma sentinel lymph nodes identifies immune cell signatures associated with metastasis 2025 ·JCI Insight ·Eric Engelbrecht, (unknown), (unknown), (unknown), (unknown), Sabine Waigel, Eric C. Rouchka, Julia H. Chariker, (unknown), Jason Chesney, Kelly M. McMasters, Corey T. Watson, Kavitha Yaddanapudi	1
3	Survival Outcomes in Stage III to IV Melanoma Before and After the Immunotherapy Era: Persistent Racial and Socioeconomic Disparities 2025 ·JCO Oncology Practice ·(unknown), (unknown), (unknown), Maiying Kong, Goetz Kloecker, Jason Chesney	0
4	Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081 2025 ·Journal for ImmunoTherapy of Cancer ·Greg Andrew Durm, Hirva Mamdani, Sandra K. Althouse, Susan M. Perkins, Salma K. Jabbour, Apar Kishor Ganti, Shadia I. Jalal, Jason Chesney, Jarushka Naidoo, Borys Hrinczenko, Mary J. Fidler, Ticiana Leal, Lawrence Feldman, Naomi Fujioka, Nasser H. Hanna	1
5	Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma 2025 ·The Oncologist ·J. Randolph Hecht, (unknown), Elena Garralda, Hong Jae Chon, Antonia Digklia, Sylvie Rottey, M. Martín Jiménez, Marya Chaney, (unknown), Tatiana Lawrence, (unknown), Ali Hamidi, Jason Chesney	1
6	119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study 2023 ·Immuno-Oncology Technology ·Theresa Medina, Jason Chesney, Eric D. Whitman, Harriet M. Kluger, Sajeve Thomas, Amod Sarnaik, John M. Kirkwood, James Larkin, Jeffrey S. Weber, Omid Hamid, Martin Wermke, Friedrich Graf Finckenstein, Jeffrey Chou, Brian Gastman, (unknown), Xiao Wu, Wen Shi, (unknown)	7
7	1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study 2023 ·Annals of Oncology ·(unknown), (unknown), Sajeve Thomas, Jason Chesney, (unknown), (unknown), Theresa Medina, Mirjana Ziemer, Eric D. Whitman, Friedrich Graf Finckenstein, Jeffrey Chou, Xiao Wu, (unknown), Wen Shi, Amod A. Sarnaik	10
8	Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients 2023 ·Current Oncology ·(unknown), Gabriela Schneider, Alagammai Kaliappan, Robert Buscaglia, Guy Brock, (unknown), Donald M. Miller, Jason Chesney, Nichola C. Garbett	3
9	Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy 2023 ·Science Advances ·(unknown), Howard Donninger, (unknown), (unknown), (unknown), Xiang Zhang, (unknown), Chi Li, (unknown), Robert A. Mitchell, Alfred Zippelius, John W. Eaton, Jason Chesney, Kavitha Yaddanapudi	42
10	727 Interim phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Martin Gutierrez, Melissa Johnson, David Sommerhalder, Wells A. Messersmith, Haeseong Park, Muhammad Furqan, Jason Chesney, Ryan Bjordahl, Lingmin Zeng, Péter Szabó, Yu‐Waye Chu, (unknown), (unknown), Jeffrey Chou, David S. Hong	1
11	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study 2020 ·Clinical Cancer Research ·Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason Chesney, (unknown), Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gümüşçü, Jonathan D. Cheng, Wendy Snyder, Lillian L. Siu	83
12	Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells 2020 ·Genes ·(unknown), Conor O’Neill, (unknown), (unknown), Eric C. Rouchka, Sabine Waigel, Jorge G. Gómez-Gutiérrez, Jason Chesney, Yoannis Imbert-Fernandez	22
13	1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone 2020 ·Annals of Oncology ·Caroline Robert, Georgina V. Long, James Larkin, Jedd D. Wolchok, Jessica C. Hassel, Dirk Schadendorf, F. Stephen Hodi, Célèste Lebbé, Jean‐Jacques Grob, Kenneth F. Grossmann, John Wagstaff, Jason Chesney, Marcus O. Butler, Oliver Bechter, Iván Márquez‐Rodas, Anna C. Pavlick, Sandra Re, Wim van Dijck, Michael A. Postow, Paolo A. Ascierto	7
14	Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy 2019 ·Cancers ·(unknown), (unknown), (unknown), Stephanie P. Vega, (unknown), Kelly M. McMasters, Jason Chesney, Jorge G. Gómez-Gutiérrez, Yoannis Imbert-Fernandez	17
15	Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers 2018 ·International Journal of Cancer ·Susmita Mondal, Debarshi Roy, Sayantani Sarkar Bhattacharya, Ling Jin, Deok‐Beom Jung, Song Zhang, Eleftheria Kalogera, Julie Staub, Yaxian Wang, (unknown), Ashwani Khurana, Jeremy Chien, Sucheta Telang, Jason Chesney, Gilles Tapolsky, (unknown), Viji Shridhar	120
16	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma breakdown → 2018 ·Science Translational Medicine ·Scott J. Rodig, Daniel Gusenleitner, Donald Jackson, Evisa Gjini, Anita Giobbie‐Hurder, Chelsea Jin, Han Chang, Scott B. Lovitch, Christine E. Horak, Jeffrey S. Weber, Jason L. Weirather, Jedd D. Wolchok, Michael A. Postow, Anna C. Pavlick, Jason Chesney, F. Stephen Hodi	408
17	5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma 2018 ·The American Journal of the Medical Sciences ·(unknown), (unknown), (unknown), (unknown), N. Shesh, Jianmin Pan, Jason Chesney, Donald M. Miller	1
18	Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and Then Ras Proteins Are Required for Tumor Initiation and Progression 2013 ·Journal of Biological Chemistry ·Yongqing Liu, Ester Sànchez‐Tilló, Xiaoqin Lu, Li Huang, Brian F. Clem, Sucheta Telang, Alfred B. Jenson, Míriam Cuatrecasas, Jason Chesney, Antonio Postigo, Douglas C. Dean	28
19	Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma 2011 ·Clinical Cancer Research ·Kevin B. Kim, Jason Chesney, Douglas Robinson, Humphrey Gardner, Michael Shi, John M. Kirkwood	100
20	Targeted disruption of inducible 6-phosphofructo-2-kinase results in embryonic lethality 2005 ·Biochemical and Biophysical Research Communications ·Jason Chesney, Sucheta Telang, Abdullah Yalçın, Amy Clem, (unknown), Richard Bucala	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact